Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Multicenter, Randomized, Clinical Trial to Study the Effects of Multiple Doses of MK-1029 on the Late Asthmatic Response to Lung Allergen Challenge in Asthmatics

Next Previous
Search
Trial Profile

A Two-Part, Multicenter, Randomized, Clinical Trial to Study the Effects of Multiple Doses of MK-1029 on the Late Asthmatic Response to Lung Allergen Challenge in Asthmatics

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 1029 (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 06 Feb 2019 Trial focus, outcome measures, treatment arms has been amended.
  • 09 Feb 2012 Actual patients number is 16 as reported by ClinicalTrials.gov.
  • 30 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top